[Back to Overwiew]  [IACM Homepage]

IACM-Bulletin of 01 April 2007

Science: THC relaxes the colon and may be useful in irritable bowel syndrome

According to a study conducted at the Mayo Clinic, USA, with 52 volunteers the application of THC relaxed the large intestine. Participants were randomly assigned to receive either a single dose of 7.5 mg oral THC or a placebo. The effects of THC on the colon were measured one hour after medication, during fasting and one hour after a meal rich in calories (1000 kcal). THC caused a significant increase in colonic compliance, a non-significant increase of relaxation in fasting colonic tone and a significant inhibition of colonic tone after the meal.

The authors concluded that THC relaxes the colon and reduces the colonic motility and tone after a meal. "The potential for CBR [cannabinoid receptors] to modulate colonic motor function in diarrheal disease such as irritable bowel syndrome deserves further study," they wrote.

(Source: Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007 Mar 29; [Electronic publication ahead of print)

USA: Medical cannabis bill defeated in New Hampshire House of Representatives

USA: Medical cannabis bill defeated in New Hampshire House of Representatives

By a slender margin, lawmakers in New Hampshire decided on 28 March against letting people with debilitating illnesses use cannabis for pain relief or other medical purposes. The 186-177 vote in the House of Representatives stopped a bill that would have decriminalized the drug's use for patients under the care of a physician for severe illnesses such as cancer, AIDS or multiple sclerosis.

Meanwhile, a move to legalize cannabis for medical purposes cleared its first legislative hurdle in the state of Connecticut. On 21 March the Judiciary Committee voted 31-8 in favour of the legislation. This year's version would allow residents, 18-years-old and older, with a debilitating medical condition diagnosed by a physician, to cultivate and use cannabis to relieve the symptoms of their disease.

Alaska, Arizona, California, Colorado, Hawaii, Maine, Nevada, Oregon, Rhode Island, Vermont and Washington have already legalized the medical use of cannabis. The legislature of New Mexico also passed a bill that would legalize the medical use of cannabis in March 2007 and Governor Bill Richardson, who still has to sign the bill, supports the measure.

(Sources: Concord Monitor of 29 March 2007, Associated Press of 21 March 2007)

News in brief

Canada: Neuropathic pain
In a consensus statement the Canadian Pain Society issued guidelines for the pharmacological management of chronic neuropathic pain. Analgesic agents recommended for first-line treatments are certain antidepressants and anticonvulsants (gabapentin and pregabalin). Second-line treatments recommended are serotonin noradrenaline reuptake inhibitors and topical lidocaine. Opioids are recommended as third-line treatments. Recommended fourth-line treatments include cannabinoids, methadone and anticonvulsants with lesser evidence of efficacy. (Source: Moulin DE, et al. Pain Res Manag 2007;12(1):13-21.)

Science: Tinnitus
In an animal model of tinnitus the number of nerve cells in a certain brain region (ventral cochlear nucleus) with CB1 receptors decreased. This brain region has an important function in the auditory system. Researchers concluded that their results suggest "that CB1 receptors in the cochlear nucleus may be important for auditory function and that a down-regulation of CB1 receptors in the ventral cochlear nucleus may be related to the development of tinnitus." (Source: Zheng Y, et al. Hear Res. 2007 Feb 16; [Electronic publication ahead of print])

A glimpse @ the past

One year ago

Two years ago

[Back to Overwiew]  [IACM Homepage]

up

Online Events 2020

Please find all information of IACM Online Events including free videos of the webinars here.

Conference 2022

The 12th IACM Conference on Cannabinoids in Medicine will be we be held on 20 and 21 October 2022 together with the Swiss SSCM in Basel/Switzerland.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.